SAB Biotherapeutics Inc [SABS] stock prices are down -0.25% to $3.99 at the moment. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The SABS shares have gain 6.12% over the last week, with a monthly amount glided 23.15%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
SAB Biotherapeutics Inc [NASDAQ: SABS] stock has seen the most recent analyst activity on September 17, 2025, when Leerink Partners initiated its Outperform rating and assigned the stock a price target of $7. On October 09, 2024, Craig Hallum initiated with a Buy rating and assigned a price target of $11 on the stock. Oppenheimer started tracking the stock assigning an Outperform rating and suggested a price target of $12 on August 28, 2024. Chardan Capital Markets initiated its recommendation with a Buy and recommended $17 as its price target on November 05, 2021.
The stock price of SAB Biotherapeutics Inc [SABS] has been fluctuating between $1.00 and $6.60 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. SAB Biotherapeutics Inc [NASDAQ: SABS] shares were valued at $3.99 at the most recent close of the market. An investor can expect a potential return of 75.44% based on the average SABS price forecast.
Analyzing the SABS fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at 0.1, Equity is 0.33 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 3.89 points at the first support level, and at 3.79 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.05, and for the 2nd resistance point, it is at 4.12.
Ratios To Look Out For
It’s worth pointing out that SAB Biotherapeutics Inc [NASDAQ:SABS]’s Current Ratio is 10.50. Further, the Quick Ratio stands at 10.50, while the Cash Ratio is 2.73. Considering the valuation of this stock, the price to sales ratio is 1726.85, the price to book ratio is 1.15.
